Mark R Pittelkow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1395443/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Skin Cancer Knowledge, Attitudes and Sun Protection Practices in the Hispanic Population: A Cross-Sectional Survey. Journal of Racial and Ethnic Health Disparities, 2023, 10, 1293-1303.	3.2	4
2	Deep learning for dermatologists: Part II. Current applications. Journal of the American Academy of Dermatology, 2022, 87, 1352-1360.	1.2	27
3	Comorbidities and diabetic complications in patients with necrobiosis lipoidica. Journal of the American Academy of Dermatology, 2022, 86, 891-894.	1.2	2
4	Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: Diagnosis and management. Journal of the American Academy of Dermatology, 2022, 86, 1167-1169.	1.2	7
5	Clinical and morphological features of necrobiosis lipoidica. Journal of the American Academy of Dermatology, 2022, 86, 1133-1135.	1.2	9
6	Necrobiosis lipoidica-associated cutaneous malignancy. Journal of the American Academy of Dermatology, 2022, 86, 1428-1429.	1.2	3
7	Deep learning for dermatologists: Part I. Fundamental concepts. Journal of the American Academy of Dermatology, 2022, 87, 1343-1351.	1.2	20
8	Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study. Journal of Investigative Dermatology, 2022, 142, 2109-2116.e4.	0.7	20
9	Histopathologic features of necrobiosis lipoidica. Journal of Cutaneous Pathology, 2022, 49, 692-700.	1.3	6
10	Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. British Journal of Dermatology, 2022, 187, 650-658.	1.5	19
11	Trends in Medicare utilization and reimbursement for electronic brachytherapy following 2016 billing code changes. Journal of the American Academy of Dermatology, 2021, 84, 1154-1155.	1.2	0
12	Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome. JAAD Case Reports, 2021, 9, 24-27.	0.8	7
13	Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon. JAMA Network Open, 2021, 4, e217934.	5.9	24
14	Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination. Leukemia and Lymphoma, 2021, 62, 2554-2555.	1.3	24
15	Primary cutaneous epidermotropic marginal zone B-cell lymphoma treated with total skin electron beam therapy. JAAD Case Reports, 2021, 15, 15-18.	0.8	3
16	26941 The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma in a random sampling representative of the general population. Journal of the American Academy of Dermatology, 2021, 85, AB26.	1.2	0
17	How to Sequence Therapies in Mycosis Fungoides. Current Treatment Options in Oncology, 2021, 22, 101.	3.0	3
18	25713 Ruxolitinib cream in the treatment of cutaneous lichen planus. Journal of the American Academy of Dermatology, 2021, 85, AB10.	1.2	0

#	Article	IF	CITATIONS
19	25240 Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris: A single arm, open-label exploratory study. Journal of the American Academy of Dermatology, 2021, 85, AB55.	1.2	0
20	Bexarotene. Mayo Clinic Proceedings, 2021, 96, 2519-2522.	3.0	1
21	Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study. Journal of the American Academy of Dermatology, 2021, 85, 969-971.	1.2	4
22	Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor. Anti-Cancer Drugs, 2021, 32, 474-475.	1.4	1
23	Consolidation of US dermatology practices. International Journal of Dermatology, 2021, , .	1.0	Ο
24	Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2020, 82, 846-853.	1.2	14
25	Improving Access to Care Through the Establishment of a Local, Teledermatology Network. Telemedicine Journal and E-Health, 2020, 26, 935-940.	2.8	14
26	Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin. JAAD Case Reports, 2020, 6, 19-22.	0.8	3
27	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 2020, 12, .	12.4	32
28	15591 CD4+ small/medium T-cell lymphoproliferative disorder: A Mayo Enterprise experience. Journal of the American Academy of Dermatology, 2020, 83, AB42.	1.2	0
29	A case of pediatric lymphomatoid papulosis treated with photodynamic therapy and narrowband ultraviolet B. Pediatric Dermatology, 2020, 37, 881-883.	0.9	4
30	Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. JCO Precision Oncology, 2020, 4, 319-334.	3.0	67
31	Use of Skin Cancer Procedures, Medicare Reimbursement, and Overall Expenditures, 2012-2017. JAMA Network Open, 2020, 3, e2025139.	5.9	6
32	The policy dimensions, regulatory landscape, and market characteristics of teledermatology in the United States. JAAD International, 2020, 1, 202-207.	2.2	6
33	The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, 80, 626-632.e1.	1.2	16
34	Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial Myxedema: A Case Series. Thyroid, 2019, 29, 692-699.	4.5	12
35	Syringotropic and folliculotropic mycosis fungoides with mycosis fungoides–associated vasculopathic ulcers. JAAD Case Reports, 2019, 5, 231-233.	0.8	4
36	Impact of standardized templates and skin cancer learning modules for teledermatology consultations. International Journal of Dermatology, 2019, 58, 1423-1429.	1.0	9

Mark R Pittelkow

#	Article	IF	CITATIONS
37	Density and distribution of acral melanocytic nevi and acral melanomas on the plantar surface of the foot. Journal of the American Academy of Dermatology, 2019, 80, 790-792.e2.	1.2	5
38	Cutaneous Eruption Heralding Squamous Cell Carcinoma of the Lung: Answer. American Journal of Dermatopathology, 2019, 41, 773-774.	0.6	0
39	Dermoscopic Description of Fibroepithelioma of Pinkus with Negative Network. Dermatology Practical and Conceptual, 2019, 9, 246-247.	0.9	2
40	Prevalence of Delusional Infestation—A Population-Based Study. JAMA Dermatology, 2018, 154, 615.	4.1	18
41	An effective game-based learning intervention for improving melanoma recognition. Journal of the American Academy of Dermatology, 2018, 79, 587-588.	1.2	4
42	Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case–control study. Journal of the American Academy of Dermatology, 2018, 79, 913-920.e1.	1.2	17
43	Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review. JAAD Case Reports, 2018, 4, 789-793.	0.8	3
44	Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome. American Journal of Surgical Pathology, 2018, 42, 1647-1652.	3.7	23
45	Dermoscopic features of cutaneous Langerhans cell histiocytosis. European Journal of Dermatology, 2018, 28, 88-89.	0.6	Ο
46	Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic. Journal of the American Academy of Dermatology, 2017, 76, 683-688.	1.2	15
47	Acral Melanoma and Mechanical Stress on the Plantar Surface of the Foot. New England Journal of Medicine, 2017, 377, 395-396.	27.0	50
48	Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study. Journal of the American Academy of Dermatology, 2017, 77, 719-727.	1.2	34
49	Skin-Limited Graft-versus-Host Disease after Pancreatic Transplantation. Case Reports in Transplantation, 2017, 2017, 1-3.	0.3	0
50	Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. International Journal of Dermatology, 2016, 55, e431-9.	1.0	28
51	Concomitant pemphigus herpetiformis and sarcoidosis. JAAD Case Reports, 2016, 2, 436-438.	0.8	1
52	Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. Mayo Clinic Proceedings, 2016, 91, 1384-1394.	3.0	145
53	Calciphylaxis: A Disease of Pannicular Thrombosis. Mayo Clinic Proceedings, 2016, 91, 1395-1402.	3.0	42
54	Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology. Experimental Dermatology, 2016, 25, 839-846.	2.9	63

#	Article	IF	CITATIONS
55	Gene Expression Profiling in Cutaneous Melanoma: Caveats for Clinicians. Mayo Clinic Proceedings, 2016, 91, 1147-1148.	3.0	6
56	Thyroid Ophthalmopathy, Dermopathy, and Acropachy. New England Journal of Medicine, 2016, 375, 261-261.	27.0	6
57	Epidermal reference genes at the forefront of data interpretation. Experimental Dermatology, 2015, 24, 738-739.	2.9	0
58	A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma. Melanoma Research, 2015, 25, 406-411.	1.2	20
59	Personalized treatment of Sézary syndrome by targeting a novel <i><scp>CTLA</scp>4</i> : <i><scp>CD</scp>28</i> fusion. Molecular Genetics & Genomic Medicine, 2015, 3, 130-136.	1.2	73
60	Dermatologic Disorders in 118 Patients with Autoimmune (Immunoglobulin G4-Related) Pancreatitis: A Retrospective Cohort Analysis. American Journal of Clinical Dermatology, 2015, 16, 125-130.	6.7	5
61	Pseudo Pemphigus Phenotypes in Mice with Inactivated Desmoglein 3. American Journal of Pathology, 2015, 185, 3125-3127.	3.8	5
62	Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients. International Journal of Dermatology, 2015, 54, 424-437.	1.0	18
63	Isotretinoin Exposure and Risk of Celiac Disease. PLoS ONE, 2015, 10, e0135881.	2.5	2
64	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood, 2014, 123, 3007-3015.	1.4	158
65	Isotretinoin Exposure and Risk of Inflammatory Bowel Disease. JAMA Dermatology, 2014, 150, 1322.	4.1	40
66	Signalling protein complexes isolated from primary human skinâ€resident <scp>T</scp> cells can be analysed by <scp>M</scp> ultiplex <scp>IP</scp> â€ <scp>FCM</scp> . Experimental Dermatology, 2014, 23, 272-273.	2.9	8
67	Immunomodulation of malignant melanoma by contact sensitizing agents. Expert Review of Clinical Immunology, 2014, 10, 63-76.	3.0	11
68	Increased Immunoglobulin (Ig) G4–Positive Plasma Cell Density and IgG4/IgG Ratio Are Not Specific for IgG4-Related Disease in the Skin. American Journal of Clinical Pathology, 2014, 141, 234-238.	0.7	26
69	Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents. Journal of the American Academy of Dermatology, 2014, 70, e136-e137.	1.2	6
70	A population-based study of the association between bullous pemphigoid and neurologic disorders. Journal of the American Academy of Dermatology, 2014, 71, 1191-1197.	1.2	81
71	Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. Journal of the American Academy of Dermatology, 2014, 71, 92-99.	1.2	101
72	Sézary Syndrome. Surgical Pathology Clinics, 2014, 7, 191-202.	1.7	4

#	Article	IF	CITATIONS
73	Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. Journal of Drugs in Dermatology, 2014, 13, 111-8.	0.8	31
74	CD4+CD25+FOXP3+ malignant T cells in Sézary syndrome are not necessarily functional regulatory T cells. Journal of the American Academy of Dermatology, 2013, 69, 485-489.	1.2	8
75	Activation of the epidermal growth factor receptor promotes lymphangiogenesis in the skin. Journal of Dermatological Science, 2013, 71, 184-194.	1.9	31
76	IgG4-Related Skin Disease. JAMA Dermatology, 2013, 149, 1439.	4.1	5
77	Pediatric melanoma: Analysis of an international registry. Cancer, 2013, 119, 4012-4019.	4.1	71
78	Immunolocalization of the Tumor-Sensitive Calmodulin-Like Protein CALML3 in Normal Human Skin and Hyperproliferative Skin Disorders. PLoS ONE, 2013, 8, e62347.	2.5	14
79	Pemphigus Vulgaris Autoantibody Profiling by Proteomic Technique. PLoS ONE, 2013, 8, e57587.	2.5	92
80	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. Blood, 2013, 122, 841-841.	1.4	0
81	Reply to the Editor—Atrial Fibrillation: An Inflammatory and Autoimmune Disorder. Heart Rhythm, 2012, 9, e2-e3.	0.7	1
82	Comments on: Stricker and Middelveen. Psychosomatics, 2012, 53, 505-506.	2.5	1
83	Delusional Infestation is Typically Comorbid with Other Psychiatric Diagnoses: Review of 54 Patients Receiving Psychiatric Evaluation at Mayo Clinic. Psychosomatics, 2012, 53, 258-265.	2.5	43
84	Cutaneous small-vessel vasculitis associated with solid organ malignancies: The Mayo Clinic experience, 1996 to 2009. Journal of the American Academy of Dermatology, 2012, 66, e55-e65.	1.2	54
85	Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: Experience with 218 patients over 30 years at Mayo Clinic. Journal of the American Academy of Dermatology, 2012, 67, 100-106.	1.2	64
86	From Furuncle to Axillary Web Syndrome: Shedding Light on Histopathology and Pathogenesis. Dermatology, 2012, 224, 110-114.	2.1	42
87	Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010. Journal of the American Academy of Dermatology, 2012, 67, e179-e185.	1.2	112
88	Sézary syndrome: A study of 176 patients at Mayo Clinic. Journal of the American Academy of Dermatology, 2012, 67, 1189-1199.	1.2	53
89	Human Herpesviruses 6, 7, and 8 From a Dermatologic Perspective. Mayo Clinic Proceedings, 2012, 87, 1004-1014.	3.0	39
90	Randomized controlled trial of acitretin versus placebo in patients at highâ€risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer, 2012, 118, 2128-2137.	4.1	69

#	Article	IF	CITATIONS
91	Cutaneous lymphatics and chronic lymphedema of the head and neck. Clinical Anatomy, 2012, 25, 72-85.	2.7	11
92	Angiosarcoma in a patient with congenital nonhereditary lymphedema. Cutis, 2012, 90, 248-51.	0.3	6
93	Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology, 2011, 64, 91-96.	1.2	59
94	Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. Journal of the American Academy of Dermatology, 2011, 65, 673-674.	1.2	11
95	Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology, 2011, 64, 352-404.	1.2	154
96	Genome-Wide Expression Profiling of Five Mouse Models Identifies Similarities and Differences with Human Psoriasis. PLoS ONE, 2011, 6, e18266.	2.5	160
97	Paraneoplastic autoimmune multiorgan syndrome: 20 years after. International Journal of Dermatology, 2011, 50, 905-914.	1.0	98
98	Transcriptional Profiling after Lipid Raft Disruption in Keratinocytes Identifies Critical Mediators of Atopic Dermatitis Pathways. Journal of Investigative Dermatology, 2011, 131, 46-58.	0.7	52
99	Quantitative assessment of scleroderma by surface wave technique. Medical Engineering and Physics, 2011, 33, 31-37.	1.7	53
100	Delusional Infestation, Including Delusions of Parasitosis. Archives of Dermatology, 2011, 147, 1041.	1.4	36
101	Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology, 2011, 29, 2598-2607.	1.6	550
102	Myelodysplastic Syndrome Presenting as Generalized Granulomatous Dermatitis. Archives of Dermatology, 2011, 147, 331.	1.4	37
103	Hyperpigmentation–a case study. Australian Family Physician, 2011, 40, 701-2.	0.5	3
104	Iron, genes, and viruses: the porphyria cutanea tarda triple threat. Cutis, 2011, 88, 73-6.	0.3	2
105	The Hazards of Moist Toilet Paper. Archives of Dermatology, 2010, 146, 886-90.	1.4	43
106	Case report: Positron emission tomography/computed tomography: use for initial staging of malignant melanoma. International Journal of Dermatology, 2010, 49, 1056-1058.	1.0	3
107	Identification of the Effect of Amphiregulin on Keratinocytes and T Cells in Psoriasis. Psoriasis Forum, 2010, 16a, 4-8.	0.1	1
108	Folliculotropic Mycosis Fungoides. Archives of Dermatology, 2010, 146, 607-13.	1.4	132

#	Article	IF	CITATIONS
109	Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma. Cancer Prevention Research, 2010, 3, 1277-1283.	1.5	36
110	Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Cytokine, 2010, 49, 287-293.	3.2	5
111	Large Sample of Nephrogenic Systemic Fibrosis Cases From a Single Institution. Archives of Dermatology, 2009, 145, 1095-102.	1.4	20
112	Fatal Cytotoxic Cutaneous Lymphoma Presenting as Ulcerative Psoriasis. Archives of Dermatology, 2009, 145, 801-8.	1.4	17
113	Calmodulin-Like Protein Upregulates Myosin-10 in Human Keratinocytes and Is Regulated during Epidermal Wound Healing In Vivo. Journal of Investigative Dermatology, 2009, 129, 765-769.	0.7	16
114	Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Experimental Dermatology, 2009, 18, 764-770.	2.9	124
115	Constrictive bronchiolitis associated with paraneoplastic autoimmune multiâ€organ syndrome. Respirology, 2009, 14, 129-133.	2.3	61
116	Unusual cutaneous manifestations of B-cell chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2009, 60, 772-780.	1.2	48
117	John Martin Wood (1938–2008) – Pioneering biochemist, educator and communicator. Experimental Dermatology, 2008, 17, 579-583.	2.9	1
118	Transglutaminase Autoantibodies in Dermatitis Herpetiformis and Celiac Sprue. Journal of Investigative Dermatology, 2008, 128, 332-335.	0.7	55
119	Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. Mayo Clinic Proceedings, 2008, 83, 825-846.	3.0	120
120	Staphylococcal scalded skin syndrome and toxic shock syndrome after tooth extraction. Journal of the American Academy of Dermatology, 2008, 59, 342-346.	1.2	15
121	Cocaine abuse: Dermatologic manifestations and therapeutic approaches. Journal of the American Academy of Dermatology, 2008, 59, 483-487.	1.2	80
122	A Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 573-579.	1.3	25
123	Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 (RANTES). Blood, 2008, 112, 378-378.	1.4	2
124	Acute Carpal Tunnel Syndrome Preceded by 5 Years of Unusual Skin Changes. Archives of Neurology, 2007, 64, 447.	4.5	2
125	Facial edema and crusted patches: A precursor to life-threatening acute systemic lupus erythematosus. Journal of the American Academy of Dermatology, 2007, 56, S126-S127.	1.2	5
126	Calciphylaxis: Natural history, risk factor analysis, and outcome. Journal of the American Academy of Dermatology, 2007, 56, 569-579.	1.2	454

8

#	Article	IF	CITATIONS
127	Photoprotection. Lancet, The, 2007, 370, 528-537.	13.7	281
128	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 364-380.	3.0	331
129	Physiological effects of ultrasound mist on fibroblasts. International Journal of Dermatology, 2007, 46, 587-593.	1.0	54
130	Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Experimental Dermatology, 2007, 16, 28-36.	2.9	58
131	Structural and functional alterations in the ?2-adrenoceptor are caused by a point mutation in patients with atopic eczema. Experimental Dermatology, 2007, 16, 807-813.	2.9	13
132	UVB-induced Epidermal Growth Factor Receptor Phosphorylation is Critical for Downstream Signaling and Keratinocyte Survival ¶. Photochemistry and Photobiology, 2007, 72, 135-140.	2.5	3
133	Cutaneous complications of intravesical treatments for bladder cancer: Granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy. Journal of the American Academy of Dermatology, 2006, 55, 328-331.	1.2	21
134	Peptide Vaccination of Patients With Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 352-360.	1.3	52
135	Human Papillomavirus Isolated from Transplant-Associated Porokeratoses of Mibelli Responsive to Topical 5% Imiquimod Cream. Dermatologic Surgery, 2006, 32, 858-861.	0.8	18
136	Adrenergic and Cholinergic Control in the Biology of Epidermis: Physiological and Clinical Significance. Journal of Investigative Dermatology, 2006, 126, 1948-1965.	0.7	249
137	Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. Journal of Investigative Dermatology, 2006, 126, 2490-2506.	0.7	86
138	Livedoid Vasculopathy. Archives of Dermatology, 2006, 142, 1413-8.	1.4	157
139	Risk of Multiple Primary Melanomas. JAMA - Journal of the American Medical Association, 2006, 295, 1516.	7.4	Ο
140	Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy. Annals of Internal Medicine, 2006, 145, 234.	3.9	113
141	A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome. American Journal of Clinical Pathology, 2006, 125, 364-74.	0.7	10
142	Plasmapheresis for refractory urticarial vasculitis in a patient with B-cell chronic lymphocytic leukemia. Journal of Drugs in Dermatology, 2006, 5, 534-7.	0.8	8
143	Psoriasis: more than skin deep. Nature Medicine, 2005, 11, 17-18.	30.7	28
144	Amphiregulin Causes Functional Downregulation of Adherens Junctions in Psoriasis. Journal of Investigative Dermatology, 2005, 124, 1134-1140.	0.7	51

#	Article	IF	CITATIONS
145	Déjà Vu All Over Again: Skin Cap Still Contains a High-Potency Glucocorticosteroid. Archives of Dermatology, 2005, 141, 801-3.	1.4	4
146	Effectiveness of Intravenous Immunoglobulin Therapy for Skin Disease Other Than Toxic Epidermal Necrolysis: A Retrospective Review of Mayo Clinic Experience. Mayo Clinic Proceedings, 2005, 80, 41-47.	3.0	44
147	Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: Development of extracutaneous lymphoma in 6 patientsa^—. Journal of the American Academy of Dermatology, 2005, 52, 991-996.	1.2	33
148	Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2005, 53, 1067-1071.	1.2	131
149	High Recurrence Rates of Squamous Cell Carcinoma after Mohs' Surgery in Patients with Chronic Lymphocytic Leukemia. Dermatologic Surgery, 2005, 31, 38-42.	0.8	45
150	Pemphigus Vulgaris IgG and Methylprednisolone Exhibit Reciprocal Effects on Keratinocytes. Journal of Biological Chemistry, 2004, 279, 2135-2146.	3.4	91
151	Antipsoriatic drug anthralin induces EGF receptor phosphorylation in keratinocytes: requirement for H2O2 generation. Experimental Dermatology, 2004, 13, 78-85.	2.9	17
152	Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, earlyâ€onset, psoriasisâ€like skin pathology: Expression of amphiregulin in the basal epidermis is also associated with synovitis. Experimental Dermatology, 2004, 13, 347-356.	2.9	90
153	Culture confluence regulates gene expression of normal human keratinocytes. Wound Repair and Regeneration, 2004, 12, 613-617.	3.0	6
154	Thomas B Fitzpatrick MD: 1948–51: The Residency Years and Preparation for Doctoral Thesis: Mayo Clinic. Journal of Investigative Dermatology, 2004, 122, xxii-xxiv.	0.7	1
155	Mitosis increases levels of secretory leukocyte protease inhibitor in keratinocytes. Biochemical and Biophysical Research Communications, 2004, 316, 407-410.	2.1	12
156	Association of porphyria cutanea tarda with hereditary hemochromatosis. Journal of the American Academy of Dermatology, 2004, 51, 205-211.	1.2	46
157	Malignant Basomelanocytic Tumor Manifesting as Metastatic Melanoma. American Journal of Surgical Pathology, 2004, 28, 1393-1396.	3.7	53
158	Pemphigus Vulgaris Acantholysis Ameliorated by Cholinergic Agonists. Archives of Dermatology, 2004, 140, 327-34.	1.4	78
159	Low-Dose Tissue Plasminogen Activator for Calciphylaxis. Archives of Dermatology, 2004, 140, 1045.	1.4	58
160	High Recurrence Rates of Basal Cell Carcinoma After Mohs Surgery in Patients With Chronic Lymphocytic Leukemia. Archives of Dermatology, 2004, 140, 985-8.	1.4	66
161	A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. Journal of Clinical Investigation, 2004, 114, 1090-1097.	8.2	55
162	A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer. Breast Cancer Research and Treatment, 2003, 80, 99-104.	2.5	25

#	Article	IF	CITATIONS
163	Localization and Regulation of Pregnancy-Associated Plasma Protein A Expression in Healing Human Skin. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4465-4471.	3.6	70
164	Cutaneous T-Cell Lymphoma. Mayo Clinic Proceedings, 2003, 78, 1054-1055.	3.0	0
165	Divergent Regulation of the Growth-promoting GeneIEX-1 by the p53 Tumor Suppressor and Sp1. Journal of Biological Chemistry, 2002, 277, 14612-14621.	3.4	49
166	Recurrent Erythema Multiforme/Stevens-Johnson Syndrome. Archives of Dermatology, 2002, 138, 1547.	1.4	37
167	Progressive generalized alopecia due to systemic amyloidosis. Journal of the American Academy of Dermatology, 2002, 46, 434-436.	1.2	22
168	Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas. Journal of the American Academy of Dermatology, 2002, 46, 95-106.	1.2	448
169	Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients. Journal of the American Academy of Dermatology, 2002, 46, 27-34.	1.2	152
170	Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome. Journal of the American Academy of Dermatology, 2002, 47, 63-67.	1.2	13
171	Primary follicular mucinosis: Long-term follow-up of patients younger than 40 years with and without clonal T-cell receptor gene rearrangement. Journal of the American Academy of Dermatology, 2002, 47, 856-862.	1.2	108
172	Extracorporeal Photopheresis and Adjuvant Aerosolized Granulocyte-Macrophage Colony-Stimulating Factor for Sézary Syndrome. Mayo Clinic Proceedings, 2002, 77, 197-200.	3.0	10
173	Guideline and quality indicators for development, purchase and use of controlled health vocabularies. International Journal of Medical Informatics, 2002, 68, 175-186.	3.3	30
174	Simultaneous analysis of oxidized and reduced glutathione in cell extracts by capillary zone electrophoresis. Biomedical Chromatography, 2002, 16, 224-228.	1.7	24
175	Suppression of tissue factor expression, cofactor activity, and metastatic potential of murine melanoma cells by theN-terminal domain of adenovirus E1A 12S protein. Journal of Cellular Biochemistry, 2002, 85, 54-71.	2.6	12
176	Okadaic acid-induced EGF receptor and MAP kinase activation does not require reactive oxygen species in primary keratinocytes. Archives of Dermatological Research, 2002, 294, 243-245.	1.9	8
177	Vitamin C Derivative Ascorbyl Palmitate Promotes Ultraviolet-B-Induced Lipid Peroxidation and Cytotoxicity in Keratinocytes. Journal of Investigative Dermatology, 2002, 119, 1103-1108.	0.7	37
178	Characterization of a novel hexameric repeat DNA sequence in the promoter of the immediate early gene, IEX-1, that mediates 11±,25-dihydroxyvitamin D3-associated IEX-1 gene repression. Oncogene, 2002, 21, 3706-3714.	5.9	25
179	Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine. International Journal of Dermatology, 2002, 41, 352-6.	1.0	6
180	H2O2 mediates oxidative stress-induced epidermal growth factor receptor phosphorylation. Toxicology Letters, 2001, 122, 205-214.	0.8	54

#	Article	IF	CITATIONS
181	Human Calmodulin-like Protein Is an Epithelial-Specific Protein Regulated during Keratinocyte Differentiation. Experimental Cell Research, 2001, 267, 216-224.	2.6	33
182	Human EGF Receptor (HER) Family and Heregulin Members Are Differentially Expressed in Epidermal Keratinocytes and Modulate Differentiation. Experimental Cell Research, 2001, 271, 315-328.	2.6	59
183	Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure. Journal of the American Academy of Dermatology, 2001, 44, 681-686.	1.2	13
184	Trichothiodystrophy: Update on the sulfur-deficient brittle hair syndromes. Journal of the American Academy of Dermatology, 2001, 44, 891-924.	1.2	281
185	Expression of an immediate early gene, IEX-1, in human tissues. Histochemistry and Cell Biology, 2001, 115, 489-497.	1.7	43
186	IEX-1, an immediate early gene, increases the rate of apoptosis in keratinocytes. Oncogene, 2001, 20, 7992-7997.	5.9	69
187	Vitamin E analog modulates UVB-induced signaling pathway activation and enhances cell survival. Free Radical Biology and Medicine, 2001, 30, 425-432.	2.9	28
188	Recombinant Tissue Plasminogen Activator for the Treatment of Cutaneous Infarctions in Antiphospholipid Antibody Syndrome. Angiology, 2001, 52, 635-639.	1.8	17
189	The Effect of Insulinâ€dependent Diabetes Mellitus on the Efficacy of Extracorporeal Photopheresis in Lateâ€stage Sézary Syndrome. Annals of the New York Academy of Sciences, 2001, 941, 206-209.	3.8	0
190	Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris–like lesions. Journal of Clinical Investigation, 2000, 106, 1467-1479.	8.2	169
191	UVB-induced Epidermal Growth Factor Receptor Phosphorylation is Critical for Downstream Signaling and Keratinocyte Survival¶. Photochemistry and Photobiology, 2000, 72, 135.	2.5	75
192	WHIM syndrome, an autosomal dominant disorder: Clinical, hematological, and molecular studies. American Journal of Medical Genetics Part A, 2000, 91, 368-376.	2.4	193
193	Melanocytes are not absent in lesional skin of long duration vitiligo. Journal of Pathology, 2000, 191, 407-416.	4.5	198
194	Anti-Psoriatic Drug Anthralin Activates JNK via Lipid Peroxidation: Mononuclear Cells are More Sensitive than Keratinocytes. Journal of Investigative Dermatology, 2000, 114, 688-692.	0.7	24
195	WHIM syndrome, an autosomal dominant disorder: Clinical, hematological, and molecular studies. American Journal of Medical Genetics Part A, 2000, 91, 368.	2.4	2
196	Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy. Journal of the American Academy of Dermatology, 2000, 43, 340-343.	1.2	9
197	Regulation of Cellular Growth by 1,25-Dihydroxyvitamin D3-Mediated Growth Factor Expression. Physiology, 1999, 14, 37-40.	3.1	2
198	UVB Activates ERK1/2 and p38 Signaling Pathways via Reactive Oxygen Species in Cultured Keratinocytes. Journal of Investigative Dermatology, 1999, 112, 751-756.	0.7	218

#	Article	IF	CITATIONS
199	H2O2 is required for UVB-induced EGF receptor and downstream signaling pathway activation. Free Radical Biology and Medicine, 1999, 27, 1197-1202.	2.9	81
200	Homocysteinemia and livedoid vasculitis. Journal of the American Academy of Dermatology, 1999, 40, 279-281.	1.2	40
201	Monoclonal gammopathies and associated skin disorders. Journal of the American Academy of Dermatology, 1999, 40, 507-535.	1.2	202
202	High-Cell-Density Phorbol Ester and Retinoic Acid Upregulate Involucrin and Downregulate Suprabasal Keratin 10 in Autocrine Cultures of Human Epidermal Keratinocytes. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 1999, 2, 138-144.	1.6	44
203	Human Epidermal Keratinocytes Upregulate Expression of the Prolactin Receptor after the Onset of Terminal Differentiation, but Do Not Respond to Prolactin. Archives of Biochemistry and Biophysics, 1999, 364, 247-253.	3.0	22
204	H2O2 Is an Important Mediator of UVB-Induced EGF-Receptor Phosphorylation in Cultured Keratinocytes. Journal of Investigative Dermatology, 1998, 110, 966-971.	0.7	172
205	Perturbed Epidermal Pterin Metabolism in Hermansky–Pudlak Syndrome. Journal of Investigative Dermatology, 1998, 111, 511-516.	0.7	11
206	Follicular mucinosis presenting as an acneiform eruption: Report of four cases. Journal of the American Academy of Dermatology, 1998, 38, 849-851.	1.2	65
207	Regulation of a Novel Immediate Early Response Gene,IEX-1,in Keratinocytes by 11±,25-Dihydroxyvitamin D3. Biochemical and Biophysical Research Communications, 1998, 251, 868-873.	2.1	42
208	A Novel Immediate Early Response Gene, IEX-1, Is Induced by Ultraviolet Radiation in Human Keratinocytes. Biochemical and Biophysical Research Communications, 1998, 253, 336-341.	2.1	47
209	Autocrine Regulation of Keratinocytes: The Emerging Role of Heparin-Binding, Epidermal Growth Factor-Related Growth Factors. Journal of Investigative Dermatology, 1998, 111, 715-721.	0.7	126
210	Up-regulation of Glucosylceramide Synthase Expression and Activity during Human Keratinocyte Differentiation. Journal of Biological Chemistry, 1998, 273, 9651-9655.	3.4	58
211	The Pathophysiological Significance of Nondesmoglein Targets of Pemphigus Autoimmunity. Archives of Dermatology, 1998, 134, 971-80.	1.4	106
212	Characterization of Skn-1a/i POU Domain Factors and Linkage to Papillomavirus Gene Expression. Journal of Biological Chemistry, 1997, 272, 15905-15913.	3.4	32
213	Plasma Protein Abnormalities and Vascular Lesions. Journal of Dermatology, 1997, 24, 732-733.	1.2	1
214	Hydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea. Journal of the American Academy of Dermatology, 1997, 36, 178-182.	1.2	170
215	Activated protein C resistance caused by factor V gene mutation: Common coagulation defect in chronic venous leg ulcers?. Journal of the American Academy of Dermatology, 1997, 36, 616-620.	1.2	26
216	Antiphospholipid syndrome and the skin. Journal of the American Academy of Dermatology, 1997, 36, 970-982.	1.2	189

#	Article	IF	CITATIONS
217	EGF-Receptor Tyrosine Kinase Inhibition Induces Keratinocyte Growth Arrest and Terminal Differentiation. Journal of Investigative Dermatology, 1997, 109, 751-756.	0.7	149
218	Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema. Archives of Dermatological Research, 1997, 289, 663-666.	1.9	31
219	Cyclosporine in the Treatment of Dermatologic Disease: An Update. Mayo Clinic Proceedings, 1996, 71, 1182-1191.	3.0	58
220	Generalized Gravis Junctional Epidermolysis Bullosa: Case Report, Laboratory Evaluation, and Review of Recent Advances. Mayo Clinic Proceedings, 1996, 71, 863-868.	3.0	9
221	1α,25-Dihydroxyvitamin D3Inhibits Normal Human Keratinocyte Growth by Increasing Transforming Growth Factor β2 Release. Biochemical and Biophysical Research Communications, 1996, 229, 618-623.	2.1	34
222	Eosinophilic vasculitis in connective tissue disease. Journal of the American Academy of Dermatology, 1996, 35, 173-182.	1.2	61
223	Detection of circulating T cells with CD4+CD7â^' immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. Journal of the American Academy of Dermatology, 1996, 35, 404-410.	1.2	132
224	GROWTH FACTORS IN HAIR ORGAN DEVELOPMENT AND THE HAIR GROWTH CYCLE. Dermatologic Clinics, 1996, 14, 559-572.	1.7	91
225	Defective calcium transport in vitiliginous melanocytes. Archives of Dermatological Research, 1996, 288, 11-13.	1.9	69
226	Overexpression and mutations ofp53 in metastatic malignant melanomas. , 1996, 67, 313-317.		58
227	The induction of the alpha-1-adrenoceptor signal transduction system on human melanocytes. Experimental Dermatology, 1996, 5, 20-23.	2.9	32
228	Microsatellite Instability in Keratoacanthoma. Cancer, 1995, 76, 1765-1771.	4.1	37
229	Catecholamines in Human Keratinocyte Differentiation. Journal of Investigative Dermatology, 1995, 104, 953-957.	0.7	118
230	Adenosine and Adenine Nucleotides Inhibit the Autonomous and Epidermal Growth Factor-Mediated Proliferation of Cultured Human Keratinocytes. Journal of Investigative Dermatology, 1995, 104, 976-981.	0.7	22
231	Cell Density and Culture Factors Regulate Keratinocyte Commitment to Differentiation and Expression of Suprabasal K1/K10 Keratins. Journal of Investigative Dermatology, 1995, 104, 271-276.	0.7	241
232	Methotrexate Therapy of Psoriasis: Differential Sensitivity of Proliferating Lymphoid and Epithelial Cells to the Cytotoxic and Growth-Inhibitory Effects of Methotrexate. Journal of Investigative Dermatology, 1995, 104, 183-188.	0.7	112
233	Epidermal growth factors and cytokines (Clinical Dermatology Series, No. 10). Journal of the American Academy of Dermatology, 1995, 32, 303-304.	1.2	0
234	Defective calcium transport in vitiliginous melanocytes. Archives of Dermatological Research, 1995, 288, 11-13.	1.9	10

#	Article	IF	CITATIONS
235	Eosinophilic vasculitis syndrome: Recurrent cutaneous eosinophilic necrotizing vasculitis. Seminars in Dermatology, 1995, 14, 106-110.	0.6	21
236	Sneddon syndrome. Seminars in Dermatology, 1995, 14, 166-172.	0.6	37
237	Sweet syndrome: Acute febrile neutrophilic dermatosis. Seminars in Dermatology, 1995, 14, 173-178.	0.6	64
238	TORCh syndrome. Seminars in Dermatology, 1995, 14, 179-186.	0.6	43
239	Mutations in the rod domain of keratin 2e in patients with ichthyosis bullosa of Siemens. Nature Genetics, 1994, 7, 485-490.	21.4	153
240	Paraneoplastic Pemphigus: A Case of Prolonged Survival. Mayo Clinic Proceedings, 1994, 69, 851-855.	3.0	55
241	Lymphomatoid papulosis: A clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. Journal of the American Academy of Dermatology, 1994, 30, 210-218.	1.2	111
242	A Homozygous Nonsense Mutation in the β3 Chain Gene of Laminin 5 (LAMB3) in Herlitz Junctional Epidermolysis Bullosa. Genomics, 1994, 24, 357-360.	2.9	218
243	Efficacy of Vitamin D3 Derivatives in the Treatment of Psoriasis Vulgaris: A Preliminary Report. Mayo Clinic Proceedings, 1993, 68, 835-841.	3.0	26
244	Lymphoma versus pseudolymphoma of the skin: Gene rearrangement study of 21 cases with clinicopathologic correlation. Journal of the American Academy of Dermatology, 1993, 29, 945-953.	1.2	53
245	Expression of p53 protein in benign and malignant epidermal pathologic conditions. Journal of the American Academy of Dermatology, 1993, 29, 741-748.	1.2	38
246	A mutational hot spot in keratin 10 (KRT 10) in patients with epidermolytic hyperkeratosis. Human Molecular Genetics, 1993, 2, 2147-2150.	2.9	55
247	The Polymerase Chain Reaction. The Journal of Dermatologic Surgery and Oncology, 1993, 19, 831-845.	0.8	3
248	Tissue Plasminogen Activator for Treatment of Livedoid Vasculitis. Mayo Clinic Proceedings, 1992, 67, 923-933.	3.0	90
249	Production of catecholamines in the human epidermis. Biochemical and Biophysical Research Communications, 1992, 189, 72-78.	2.1	114
250	T-cell receptor gene rearrangement analysis: Cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. Journal of the American Academy of Dermatology, 1991, 25, 787-796.	1.2	103
251	Trichothiodystrophy with chronic neutropenia and mild mental retardation. Journal of the American Academy of Dermatology, 1991, 24, 356-358.	1.2	20
252	Cutaneous manifestations of cryoglobulinemia: Clinical and histopathologic study of seventy-two patients. Journal of the American Academy of Dermatology, 1991, 25, 21-27.	1.2	172

Mark R Pittelkow

#	Article	IF	CITATIONS
253	Gene rearrangement analysis in lymphoid neoplasia. Clinics in Dermatology, 1991, 9, 119-128.	1.6	20
254	Growth factor-independent proliferation of normal human neonatal keratinocytes: Production of autocrine- and paracrine-acting mitogenic factors. Journal of Cellular Physiology, 1991, 146, 277-289.	4.1	88
255	Expression and Regulation of mRNA Coding for Acidic and Basic Fibroblast Growth Factor and Transforming Growth Factor1̂± in Cells Derived from Human Skin. Molecular Endocrinology, 1990, 4, 1377-1385.	3.7	30
256	Cyclosporine in the treatment of cutaneous T cell lymphoma. Journal of the American Academy of Dermatology, 1990, 23, 1084-1089.	1.2	23
257	Trichothiodystrophy: Review of sulfur-deficient brittle hair syndromes and association with the ectodermal dysplasias. Journal of the American Academy of Dermatology, 1990, 22, 705-717.	1.2	139
258	TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 1990, 61, 777-785.	28.9	601
259	Novel redistribution of myosin-containing filaments in cultured keratinocytes identified by a human monoclonal autoantibody. In Vitro Cellular & Developmental Biology, 1989, 25, 397-401.	1.0	3
260	Growth of normal human keratinocytes and fibroblasts in serum-free medium is stimulated by acidic and basic fibroblast growth factor. Journal of Cellular Physiology, 1989, 138, 511-518.	4.1	162
261	Serum-free culture of normal human melanocytes: Growth kinetics and growth factor requirements. Journal of Cellular Physiology, 1989, 140, 565-576.	4.1	130
262	Clinical and pathologic correlations in 96 patients with panniculitis, including 15 patients with deficient levels of α1-antitrypsin. Journal of the American Academy of Dermatology, 1989, 21, 1192-1196.	1.2	116
263	Differential expression of mRNA coding for heparin-binding growth factor type 2 in human cells. Journal of Cellular Physiology, 1988, 136, 297-304.	4.1	61
264	Growth of Normal Human Melanocytes in a Defined Medium. Pigment Cell & Melanoma Research, 1988, 1, 27-31.	3.6	11
265	Alpha-1-antitrypsin deficiency and panniculitis. American Journal of Medicine, 1988, 84, 80-86.	1.5	90
266	Keratinocytes Produce and Are Regulated by Transforming Growth Factors. Annals of the New York Academy of Sciences, 1988, 548, 211-224.	3.8	39
267	Protein Kinase C-Mediated Expression of Transforming Growth Factor-? in Normal Human Keratinocytes. Annals of the New York Academy of Sciences, 1988, 548, 352-353.	3.8	1
268	Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. Journal of the American Academy of Dermatology, 1988, 19, 537-541.	1.2	104
269	Sweat Gland Carcinoma Ex Eccrine Spiradenoma. American Journal of Dermatopathology, 1987, 9, 90-98.	0.6	66
270	Production and auto-induction of transforming growth factor-α in human keratinocytes. Nature, 1987, 328, 817-820.	27.8	843

#	Article	IF	CITATIONS
271	New Techniques for the In Vitro Culture of Human Skin Keratinocytes and Perspectives on Their Use for Grafting of Patients With Extensive Burns. Mayo Clinic Proceedings, 1986, 61, 771-777.	3.0	204
272	Two Functionally Distinct Classes of Growth Arrest States in Human Prokeratinocytes That Regulate Clonogenic Potential. Journal of Investigative Dermatology, 1986, 86, 410-417.	0.7	74
273	Free Radical Reduction by Thioredoxin Reductase at the Surface of Normal and Vitiliginous Human Keratinocytes. Journal of Investigative Dermatology, 1986, 87, 728-732.	0.7	75
274	Normal and transformed human prokeratinocytes express divergent effects of a tumor promoter on cell cycle-mediated control of proliferation and differentiation. Carcinogenesis, 1985, 6, 1181-1187.	2.8	52
275	Secondary neuroendocrine carcinomas of the skin. Journal of the American Academy of Dermatology, 1985, 13, 134-142.	1.2	38
276	Integrated control of growth and differentiation of normal human prokeratinocytes cultured in serum-free medium: Clonal analyses, growth kinetics, and cell cycle studies. Journal of Cellular Physiology, 1984, 121, 31-44.	4.1	399
277	The clinicopathologic spectrum of lymphomatoid papulosis: Study of 31 cases. Journal of the American Academy of Dermatology, 1983, 8, 81-94.	1.2	161
278	Eosinophilic spongiosis: A clinicopathologic review of seventy-one cases. Journal of the American Academy of Dermatology, 1983, 8, 337-343.	1.2	65
279	Coal tar, ultraviolet light, and cancer. Journal of the American Academy of Dermatology, 1981, 4, 234-235.	1.2	7
280	Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. Journal of the American Academy of Dermatology, 1980, 3, 612-615.	1.2	85